• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    3 Top Pharma Stocks on the TSX and TSXV Year-to-Date

    Investing News Network
    Oct. 10, 2019 03:30PM PST
    Pharmaceutical Investing
    TSX:APLI

    Canada’s pharmaceutical industry is a key contributor to the global pharma market. Here are 5 top pharma stocks on the TSX and TSXV.

    Click here to read the latest top pharma stocks article.

    While small in comparison to its neighbor in the south, the Canadian pharmaceutical industry has positioned itself firmly on the global map thanks to developments in medicine and exciting new opportunities, according to a 2018 report from Research and Markets.

    Similarly, research firm Global Data estimates that the industry will grow from US$22.6 billion in 2016 to roughly US$25 billion by 2021, suggesting that with slow and steady growth there will be more in store from the Canadian pharmaceutical market in the years ahead.

    Overall, the Canadian pharmaceutical market is the 10th largest in the world and accounts for 2 percent of the global market. With a population that’s roughly 37.4 million, Canada’s pharmaceutical market share is profound, and the country is home to companies making moves.

    On that note, with three quarters of 2019 in the books, the companies listed below have been the top-performing stocks on the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV) year-to-date.

    The list below was compiled using TradingView’s stock screener, with all numbers current as of October 10, 2019. Companies on this list had market caps between C$10 million and C$500 million at that time.

    1. Acasti Pharma (TSXV:ACST)

    Market cap: US$242.58 million; current share price: US$2.86; year-to-date gain: 150.88 percent

    Acasti Pharma is focused on advancing its cardiovascular drug, CaPre, to treat hypertriglyceridemia, a condition in which triglyceride levels are increased. Triglycerides are fats that are found in blood. CaPre is currently in a Phase 3 clinical program for the condition.

    At the end of the quarter, Acasti Pharma announced additional Phase 3 milestones for CaPre and revealed that it is on pace to release topline results for the Trilogy 1 and Trilogy 2 trials in December 2019 and January 2020, respectively.

    2. BELLUS Health (TSX:BLU)

    Market cap: C$477.92 million; current share price: C$8.63; year-to-date gain: 112.85 percent

    BELLUS Health is focused on developing treatments for chronic coughs and related hypersensitization disorders, described as conditions resulting from overreactions of the immune system.

    The company is advancing the development of its drug candidate BLU-5937, which is indicated to treat chronic coughing conditions. In July, BELLUS announced that the first patient in a Phase 2 study of BLU-5937 had been dosed to treat refractory chronic cough. The company also said a Phase 2 study of the drug for eczema will begin sometime next year.

    3. Crescita Therapeutics (TSX:CTX)

    Market cap: C$18.49 million; current share price: C$0.88; year-to-date gain: 97.75 percent

    Crestica Therapeutics is a dermatology firm working on a range of non-prescription skincare treatments.

    In its pipeline are three products: Mical (1) for psoriasis, Mical (2) for dermatological skin treatments and flexicaine, a local anesthesia for cosmetic procedures. Crescita Therapeutics is also advancing its Pliaglis topical treatment, which has approval in 29 countries for local dermal anesthesia prior to superficial dermatological procedures.

    In July, the company was granted a patent from the US Patent and Trademark Office to cover an enhanced version of Pliaglis. According to a press release, the patent will expire in 2031.

    Don’t forget to follow us @INN_LifeScience for real-time news updates!

    Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.

    pharma stockspharmaceutical industrypharmaceutical investingcanadamedexustsx:frxtsx:aplifennec
    The Conversation (0)

    Go Deeper

    AI Powered
    Person touching a cannabis plant; Australia map in flag colours.

    ASX Cannabis Stocks: 10 Biggest Companies in 2025

    Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

    5 Biggest Pharmaceutical ETFs in 2025

    Latest News

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×